

Ref : DOH/CVDC/2020/1311

Date : 8 July 2020

**Dr. Nawal Mohammed Alkaabi**  
**Consultant Physician- Internal medicine/ Hematology - Sheikh Khalifa Medical City**  
**Sheikh Khalifa Medical City**

**Subject: Abu Dhabi Health COVID19 Research Ethics Committee- Approval Letter**

Research Title:

**“Randomized, double-blinded, placebo parallel-controlled phase III clinical trial to evaluate the efficacy and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in healthy population aged 18 years and above”**

Thank you for submitting all required documents to support the review process of above-mentioned study to Abu Dhabi COVID19 Research IRB Committee.


The request has been carefully reviewed by the committee and we are pleased to inform you that the committee, after deliberation, has granted you ethical approval for the research proposal submitted.

Please note that this approval is considered as an official approval and it overrides the local committee's approval; however, you need to report to the local Research Ethics Committee in the desired institutions mentioned in the study protocol in order for us to receive the following:

1. Local REC feedback in case of anything that might warrant the review of the ethical approval given
2. Any proposed changes to the research protocol/the conduct of research
3. Any information that might affect the safety of the Human Subjects
4. Annual report to Medical Research Department about the progress of the study
5. Pre-publication request

Covid-19 IRB committee wishes you all the best in your research endeavors

Yours Sincerely,



**Dr. Asma Al Manna'ei**  
**Committee Chairman**

Cc: